Individuals Stopping Slimming Medications Regain Pounds Four Times Faster Compared to People Using Diet and Exercise

New research reveals that individuals who discontinue blockbuster slimming jabs like Wegovy and Mounjaro may regain shed pounds far faster than those who stop conventional lifestyle programs.

Findings released in a leading health publication points out that while obese individuals often shed about a fifth of their total mass while on the medication, the mass comes back at an average rate of 0.8 kg per month after stopping.

"Individuals using these drugs should be cognizant of the risk of fast rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.

Such speed of regain implies a return to pre-treatment weight in about a year and a half.

Weighing Therapies

The research, which looked at dozens of studies involving over 9,000 of participants, contrasted the effects of these new drugs with conventional dieting.

The team point out that people who lose weight through lifestyle changes alone usually experience a more gradual creep back—approximately 100 grams monthly—once they finish.

Explaining the Quick Regain

Experts propose the way of the injections explains the accelerated weight return.

These medications mimic a body's own chemical called glucagon-like peptide-1, which controls appetite.

"Artificially providing the hormone concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.

"Stopping of this GLP-1 'fix' leads to appetite is no longer kept in check, making binge eating far more likely."

A Chronic Condition?

Health authorities advise the jabs for people with weight-linked health risks, alongside recommended diet and exercise modifications.

A number of clinicians argue that, due to the high risk of relapse, the treatment might need to be life-long.

This perspective is reinforced by pharmaceutical companies, who state that the results "underscore the long-term character of excess weight," akin to managing diseases like high blood pressure.

Patient Experiences

Users who have discontinued the jabs describe a intense resurgence of cravings.

"I experienced something activating and I was suddenly starving," said a patient.

The struggle is worsened if patients have not adopted permanent dietary or behavioural modifications during treatment.

Significant Adoption

Survey data indicate that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.

• Adoption is greater among females than males.
• The 40s and 50s age group shows the greatest usage rates.
• A large proportion access the drugs through private healthcare rather than public health services.

In conclusion, clinicians caution that while these medications are potent agents for shedding pounds, they are not a standalone solution and long-term success hinges on combined behavioural management.